Application of Omic Techniques to Identify New Biomarkers and Drug Targets for COVID-19

The COVID-19 pandemic caused by the SARS-CoV-2 virus has affected nearly every country and territory in the world. Although worldwide vaccination efforts have reduced the risk of serious disease outcomes, disparities in distribution have led to multiple waves of SARS-CoV-2 outbreaks and the emergenc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor Corporativo: SpringerLink (Online service)
Outros Autores: Guest, Paul C. (Editor)
Formato: Recurso Eletrônico livro eletrônico
Idioma:inglês
Publicado em: Cham : Springer International Publishing : Imprint: Springer, 2023.
Edição:1st ed. 2023.
coleção:Proteomics, Metabolomics, Interactomics and Systems Biology, 1412
Assuntos:
Acesso em linha:https://doi.org/10.1007/978-3-031-28012-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

MARC

LEADER 00000nam a22000005i 4500
001 978-3-031-28012-2
003 DE-He213
005 20251008153705.0
007 cr nn 008mamaa
008 230628s2023 sz | s |||| 0|eng d
020 |a 9783031280122  |9 978-3-031-28012-2 
024 7 |a 10.1007/978-3-031-28012-2  |2 doi 
050 4 |a QH438.4.B55 
050 4 |a R853.B54 
072 7 |a MBGR  |2 bicssc 
072 7 |a MED106000  |2 bisacsh 
072 7 |a MBGR  |2 thema 
082 0 4 |a 610.72  |2 23 
245 1 0 |a Application of Omic Techniques to Identify New Biomarkers and Drug Targets for COVID-19  |h [electronic resource] /  |c edited by Paul C. Guest. 
250 |a 1st ed. 2023. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2023. 
300 |a XI, 513 p. 87 illus., 74 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
341 0 |b Table of contents navigation  |2 onix 
341 0 |b Single logical reading order  |2 onix 
341 0 |b Short alternative textual descriptions  |2 onix 
341 0 |b Use of color is not sole means of conveying information  |2 onix 
341 0 |b Use of high contrast between text and background color  |2 onix 
341 0 |b Next / Previous structural navigation  |2 onix 
341 0 |b All non-decorative content supports reading without sight  |2 onix 
347 |a text file  |b PDF  |2 rda 
490 1 |a Proteomics, Metabolomics, Interactomics and Systems Biology,  |x 2730-6224 ;  |v 1412 
505 0 |a Chapter 1. The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology and Variants of Concern -- Chapter 2. Long-term Vaccination and Treatment Strategies for COVID-19 Disease and Future Coronavirus Pandemics -- Chapter 3. Consequences of the Lockdown - Domestic Violence during the COVID-19 Pandemic -- Chapter 4. Psychological distress impact of Coronavirus disease (COVID-19) outbreak on three continents: A systematic review and meta-analysis -- Chapter 5. A Molecular Biomarker-based Triage Approach for Targeted Treatment of Post-COVID-19 Syndrome Patients with Persistent Neurological or Neuropsychiatric Symptoms -- Chapter 6. Genetic Associations with Coronavirus Susceptibility and Disease Severity -- Chapter 7. COVID Diagnostics: from Molecules to Omics -- Chapter 8. Assessing Biomarkers in Viral Infection -- Chapter 9. Proteomic Investigation of COVID-19 Severity During the Tsunamis Second Wave in Mumbai -- Chapter 10. NMR-Metabolomics in COVID-19 Research -- Chapter 11. Potential Biomarkers of Mitochondrial Dysfunction Associated with COVID-19 Infection -- Chapter 12. Red Cell Distribution Width as a Prognostic Indicator for Mortality and ICU Admission in Patients with COVID-19 -- Chapter 13. Predicting the COVID-19 Patients Status using Chest CT Scan Findings: A Risk Assessment Model Based on Decision Tree Analysis -- Chapter 14. Inferring Recombination Events in SARS-CoV-2 Variants In Silico -- Chapter 15. Amplicon-based Nanopore Sequencing of Patients Infected by the SARS-CoV-2 Omicron (B.1.1.529) Variant in India -- Chapter 16. Perspectives on Rapid Antigen Tests for Downstream Validation and Development of Theranostics -- Chapter 17. Machine Learning and COVID-19: Lessons from SARS-CoV-2 -- Chapter 18. The Relationship between Psoriasis, COVID-19 Infection and Vaccination during Treatment of Patients -- Chapter 19. Immunogenicity of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV; Sinopharm) and Short-term Clinical Outcomes in Vaccinated Solid Organ Transplant Recipients: A Prospective Cohort Study -- Chapter 20. Spices and Biomarkers of COVID-19: A Mechanistic and Therapeutic Perspective -- Chapter 21. Antiviral Mechanisms of Curcumin and its Derivatives in Prevention and Treatment of COVID-19: A review -- Chapter 22. Evaluation of Curcumin-Piperine Supplementation in COVID-19 Patients Admitted to the Intensive Care: A Double-Blind, Randomized Controlled Trial -- Chapter 23. Chronobiological Efficacy of Combined Therapy of Pelargonium Sidoides and Melatonin in Acute and Persistent Cases of COVID-19: A Hypothetical Approach -- Chapter 24. The Potential Effect of Royal Jelly on Biomarkers Related to COVID-19 Infection and Severe Progression -- Chapter 25. Statins: Beneficial Effects in Treatment of COVID-19 -- Chapter 26. Multiplex Immunoassay Approaches Using Luminex® xMAP® Technology for the Study of COVID-19 Disease -- Chapter 27. Rapid Detection of SARS-CoV-2 Variants of Concern by Genomic Surveillance Techniques. 
520 |a The COVID-19 pandemic caused by the SARS-CoV-2 virus has affected nearly every country and territory in the world. Although worldwide vaccination efforts have reduced the risk of serious disease outcomes, disparities in distribution have led to multiple waves of SARS-CoV-2 outbreaks and the emergence of variants of concern, some of which have enhanced infectivity and ability to evade existing vaccines. Hence there is an increasing interest in understanding the evolution of viruses like SARS-CoV-2, as well as improving our capacity to effectively current and manage future pandemics. This new volume reviews the most effective omic techniques for increasing our understanding of COVID-19, to improve diagnostics, prognostics, and genomic surveillance, and to facilitate development of effective treatments and vaccines. Chapters are written by an international team of experts and explore methods in the areas of genomics, transcriptomics, proteomics, and metabolomics. Techniques used toassess physiological function at the molecular level and artificial intelligence approaches used for more effective validation and translation of biomarker candidates into clinical use are also discussed. This book is an excellent resource for researchers studying biomarkers, virology, metabolic diseases, and infectious diseases, as well as clinical scientists, physicians, drug company scientists, and healthcare workers. 
532 8 |a Accessibility summary: This PDF does not fully comply with PDF/UA standards, but does feature limited screen reader support, described non-text content (images, graphs), bookmarks for easy navigation and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. 
532 8 |a No reading system accessibility options actively disabled 
532 8 |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com 
650 0 |a Biochemical markers. 
650 0 |a Proteins. 
650 0 |a Metabolism. 
650 0 |a Genomics. 
650 1 4 |a Biomarkers. 
650 2 4 |a Proteins. 
650 2 4 |a Metabolism. 
650 2 4 |a Genomics. 
700 1 |a Guest, Paul C.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9783031280115 
776 0 8 |i Printed edition:  |z 9783031280139 
776 0 8 |i Printed edition:  |z 9783031280146 
830 0 |a Proteomics, Metabolomics, Interactomics and Systems Biology,  |x 2730-6224 ;  |v 1412 
856 4 0 |u https://doi.org/10.1007/978-3-031-28012-2 
912 |a ZDB-2-SBL 
912 |a ZDB-2-SXB 
950 |a Biomedical and Life Sciences (SpringerNature-11642) 
950 |a Biomedical and Life Sciences (R0) (SpringerNature-43708)